Monopar Therapeutics (NASDAQ:MNPR) Trading Down 3.9% – Time to Sell?

Monopar Therapeutics Inc. (NASDAQ:MNPR) shares fell 3.9% during trading on Friday . The stock traded as low as $106.50 and last traded at $106.55. Approximately 64,031 shares were traded during trading, a decline of 71% from the average daily volume of 220,969 shares. The stock had previously closed at $110.88.

Analysts Set New Price Targets

A number of analysts recently weighed in on MNPR shares. Cantor Fitzgerald cut shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price objective for the stock from $109.00 to $119.00 in a research report on Thursday, August 13th. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research report on Tuesday, June 2nd. BTIG Research lifted their target price on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. HC Wainwright boosted their target price on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $118.67.

Monopar Therapeutics Stock Down 2.9%

The firm has a market capitalization of $722.61 million, a price-to-earnings ratio of -49.61 and a beta of 1.47. The company’s fifty day moving average is $100.72 and its two-hundred day moving average is $72.97.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, equities research analysts expect that Monopar Therapeutics Inc. will post -2.94 EPS for the current year.

Hedge Funds Weigh In On Monopar Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new position in Monopar Therapeutics during the second quarter worth about $7,124,000. Bank of America Corp DE increased its stake in shares of Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after acquiring an additional 53,336 shares during the last quarter. ADAR1 Capital Management LLC raised its position in shares of Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after acquiring an additional 30,370 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in shares of Monopar Therapeutics in the 1st quarter valued at approximately $250,000. Finally, Siren L.L.C. boosted its stake in Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after acquiring an additional 57,820 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.